U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C25H32N2O2.C4H6O6
Molecular Weight 542.6206
Optical Activity UNSPECIFIED
Defined Stereocenters 3 / 3
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of DEXTROMORAMIDE D-TARTRATE

SMILES

O[C@@H]([C@H](O)C(O)=O)C(O)=O.C[C@H](CN1CCOCC1)C(C(=O)N2CCCC2)(C3=CC=CC=C3)C4=CC=CC=C4

InChI

InChIKey=ACRMUSVWIFZVSM-AEABCVGESA-N
InChI=1S/C25H32N2O2.C4H6O6/c1-21(20-26-16-18-29-19-17-26)25(22-10-4-2-5-11-22,23-12-6-3-7-13-23)24(28)27-14-8-9-15-27;5-1(3(7)8)2(6)4(9)10/h2-7,10-13,21H,8-9,14-20H2,1H3;1-2,5-6H,(H,7,8)(H,9,10)/t21-;1-,2-/m10/s1

HIDE SMILES / InChI
Molecular Formula C25H32N2O2
Molecular Weight 392.5338
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED
Molecular Formula C4H6O6
Molecular Weight 150.0868
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 2 / 2
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://books.google.ru/books?id=G7As-qawdzMC&printsec=frontcover&hl=ru#v=onepage&q&f=false | https://www.cbg-meb.nl/documenten/rapporten/2015/09/14/par-dextromoramide | https://medikamio.com/nl-nl/geneesmiddelen/palfium-tablet-5-mg/pil

Dextromoramide is a synthetic strong-acting opioid and full mu-opioid receptor agonist. Dextromoramide is a Schedule I drug illegal to possess. The current indication for Palfium® (dextromoramide) is severe acute or chronic pain requiring opioids, such as post-operative pain, and pain associated with bone fractures, malignancies and acute renal/biliary colic attacks in adults.

CNS Activity

Originator

Approval Year

Unknown
139594
Targets

Targets

Primary TargetPharmacologyConditionPotency
Agonist
2678
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Approved
8429
PALFIUM

Approved Use

Palfium® (dextromoramide) is a synthetic strong-acting opioid and full mu-opioid receptor agonist that has been registered in the Netherlands since 1974. The current indication is severe acute or chronic pain requiring opioids, such as post-operative pain, and pain associated with bone fractures, malignancies and acute renal/biliary colic attacks in adults.

Launch Date

1973
PubMed

PubMed

TitleDatePubMed
Properties and analysis of dextromoramide and its dosage forms.
1961 Jan
Effect of methadone and dextromoramide on dopamine metabolism: comparison with haloperidol and amphetamine.
1975 Dec
Patents

Patents

GB822055
3

Sample Use Guides

In Vivo Use Guide
IM: 15 mg Intra Rectal: 20 mg PO: 0.071 to 0.285 mg/kg SC: 15 mg
Route of Administration: Other
In Vitro Use Guide
Unknown
Substance Class Chemical
Created
by admin
on Fri Dec 15 17:24:30 GMT 2023
Edited
by admin
on Fri Dec 15 17:24:30 GMT 2023
Record UNII
SQR8W22C2V
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
DEXTROMORAMIDE D-TARTRATE
Common Name English
PYRROLIDINE, 1-(3-METHYL-4-MORPHOLINO-2,2-DIPHENYLBUTYRYL)-, (+)-, D-TARTRATE (1:1)
Systematic Name English
Code System Code Type Description
FDA UNII
SQR8W22C2V
Created by admin on Fri Dec 15 17:24:30 GMT 2023 , Edited by admin on Fri Dec 15 17:24:30 GMT 2023
PRIMARY
PUBCHEM
25115416
Created by admin on Fri Dec 15 17:24:30 GMT 2023 , Edited by admin on Fri Dec 15 17:24:30 GMT 2023
PRIMARY
CAS
23071-04-7
Created by admin on Fri Dec 15 17:24:30 GMT 2023 , Edited by admin on Fri Dec 15 17:24:30 GMT 2023
PRIMARY
Related Record Type Details
Structure of DEXTROMORAMIDE
ACTIVE MOIETY
NIH
NCATS
PRIVACY ACT
ACCESSIBILITY
DISCLAIMER
HHS VULNERABILITY DISCLOSURE
For language access assistance, contact the NCATS Public Information Officer
National Center for Advancing Translational Sciences (NCATS),
6701 Democracy Boulevard, Bethesda MD 20892-4874 • 301-594-8966